Adherex Technologies Inc. (NASDAQ:FENC) Stock Has Average Target Price of $17.00

Adherex Technologies Inc. (NASDAQ:FENC – Get Free Report) has earned a consensus rating of “Buy” from the six brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $17.25.

Several research firms have weighed in on FENC. Weiss Ratings upgraded shares of Adherex Technologies from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Adherex Technologies in a research note on Wednesday, September 9th. Wedbush boosted their price target on shares of Adherex Technologies from $13.00 to $16.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. B. Riley Financial restated a “buy” rating and set a $19.00 price target (up from $18.00) on shares of Adherex Technologies in a report on Monday. Finally, Zacks Research raised shares of Adherex Technologies from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 12th.

Read Our Latest Research Report on FENC

Adherex Technologies Price Performance

NASDAQ:FENC opened at $12.76 on Thursday. Adherex Technologies has a fifty-two week low of $5.65 and a fifty-two week high of $13.25. The stock’s 50-day moving average is $10.65 and its two-hundred day moving average is $9.39. The stock has a market cap of $449.41 million, a PE ratio of 155.71 and a beta of 1.29.

Adherex Technologies (NASDAQ:FENC – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $0.02. The company had revenue of $19.61 million for the quarter, compared to the consensus estimate of $18.87 million. Adherex Technologies had a return on equity of 9.58% and a net margin of 2.52%. On average, equities research analysts anticipate that Adherex Technologies will post 0.32 earnings per share for the current year.

Insider Transactions at Adherex Technologies

In other Adherex Technologies news, CFO Robert Andrade sold 75,000 shares of the company’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $11.78, for a total value of $883,500.00. Following the transaction, the chief financial officer directly owned 217,675 shares of the company’s stock, valued at $2,564,211.50. This represents a 25.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Pierre Sargis Sayad sold 12,000 shares of the firm’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $12.18, for a total value of $146,160.00. Following the sale, the insider directly owned 9,519 shares of the company’s stock, valued at $115,941.42. This trade represents a 55.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 10.73% of the company’s stock.

About Adherex Technologies

(Get Free Report)

Adherex Technologies was a biotechnology company focused on developing treatments for cancer. In 2014, the company changed its name to Fennec Pharmaceuticals Inc.; Fennec later adopted the Nasdaq ticker FENC. Fennec is a commercial-stage biopharmaceutical company focused on therapies that address complications of cancer treatment. Its principal product is PEDMARK, a sodium thiosulfate injection approved in the United States to reduce the risk of cisplatin-related hearing damage in certain pediatric patients with cancer.

See Also

Analyst Recommendations for Adherex Technologies (NASDAQ:FENC)

Receive News & Ratings for Adherex Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adherex Technologies and related companies with MarketBeat.com's FREE daily email newsletter.